Research Topics
Genomes and GenesSpecies | Vicente TorresSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Volume progression in polycystic kidney diseaseJared J Grantham
Kidney Institute and the Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA
N Engl J Med 354:2122-30. 2006..Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive enlargement of cyst-filled kidneys...
Tolvaptan in patients with autosomal dominant polycystic kidney diseaseVicente E Torres
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
N Engl J Med 367:2407-18. 2012..Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function...
Insignificant effect of secretin in rodent models of polycystic kidney and liver diseaseXiaofang Wang
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Am J Physiol Renal Physiol 303:F1089-98. 2012..Therefore, it is unlikely that by itself secretin plays a significant role in the pathogenesis of PKD and/or PLD...- Analysis of baseline parameters in the HALT polycystic kidney disease trialsVicente E Torres
Mayo Clinic College of Medicine, Rochester, Minnesota 55901, USA
Kidney Int 81:577-85. 2012.... - Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapyVicente E Torres
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Nat Rev Nephrol 8:66-8. 2012..Studies published in the past year have demonstrated a functional interaction between the main proteins implicated in these diseases and identified novel therapeutic approaches... - Vasopressin antagonists in polycystic kidney diseaseVicente E Torres
Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Semin Nephrol 28:306-17. 2008.... - Role of vasopressin antagonistsVicente E Torres
Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin J Am Soc Nephrol 3:1212-8. 2008.... - Update on autosomal dominant polycystic kidney diseaseV E Torres
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Minerva Med 98:669-91. 2007..Increased understanding of the progression of the disease and of its underlying genetic, molecular and cellular mechanisms have laid the foundations for the development of potentially effective therapies and clinical trials... - Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney diseaseVicente E Torres
Mayo Clinic College of Medicine, Rochester, MN 55901, USA
Clin J Am Soc Nephrol 2:112-20. 2007..TKV and RBF were independent predictors of GFR decline (functional disease progression). In ADPKD, RBF reduction (1) parallels TKV increase, (2) precedes GFR decline, and (3) predicts structural and functional disease progression... - Autosomal dominant polycystic kidney diseaseVicente E Torres
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Lancet 369:1287-301. 2007.... - Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunitiesV E Torres
Division of Nephrology and Hypertension, Mayo College of Medicine, Rochester, MN 55905, USA
J Intern Med 261:17-31. 2007..This review summarizes the rationale for these treatments, the results of preclinical trials and the prospects for clinical trials, some already in early phases of implementation... - Effective treatment of an orthologous model of autosomal dominant polycystic kidney diseaseVicente E Torres
Division of Nephrology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Nat Med 10:363-4. 2004.... - Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseasesVicente E Torres
Mayo Clinic College of Medicine, Eisenberg S33B, Nephrology, 200 First St SW, Rochester, MN 55905, USA
Nat Clin Pract Nephrol 2:40-55; quiz 55. 2006..Some of these have proven effective in preclinical studies, and clinical trials have begun... - Therapies to slow polycystic kidney diseaseVicente E Torres
Division of Nephrology, Mayo College of Medicine, Rochester, Minn 55905, USA
Nephron Exp Nephrol 98:e1-7. 2004..The renal selectivity and safety profile of this class of drugs make it an excellent candidate for clinical trials... - Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK ratsVicente E Torres
Mayo Foundation, Rochester, Minnesota, USA
Kidney Int 66:1766-73. 2004.... - Vasopressin antagonists in polycystic kidney diseaseVicente E Torres
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Kidney Int 68:2405-18. 2005 - Renal concentration of alpha-tocopherol: dependence on gender and lack of effect on polycystic kidney disease in Han:SPRD ratsV E Torres
Department of Nephrology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Am J Kidney Dis 31:687-93. 1998..Although these results do not support the use of vitamin E in the treatment of polycystic kidney disease, observations in the Han:SPRD rat may or may not be relevant to human polycystic kidney disease... - A case for water in the treatment of polycystic kidney diseaseVicente E Torres
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin J Am Soc Nephrol 4:1140-50. 2009..Potential pitfalls of increasing fluid intake in ADPKD patients are considered, and suggestions for how physicians may prudently implement this therapy are offered... - Inherited renal neoplasmsV E Torres
Division of Nephrology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Nephrol 11:229-38. 1998..This review provides a discussion of these mechanisms as well as the diagnosis and management of the inherited renal neoplasms... - Vascular expression of polycystin-2V E Torres
Nephrology Research Unit, Division of Nephrology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Am Soc Nephrol 12:1-9. 2001..These observations suggest a direct pathogenic role for PKD1 and PKD2 mutations in the vascular complications of ADPKD... - Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney diseaseV E Torres
Nephrology Research Unit and Division of Nephrology, Mayo Clinic, Rochester, Minn 55905, USA
Exp Nephrol 9:171-80. 2001.... - Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 StudyVicente E Torres
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Am J Kidney Dis 57:692-9. 2011..We report baseline characteristics and revised power calculations for the trial... - Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney diseaseVicente E Torres
Mayo Clinic College of Medicine, Rochester, Minnesota, MN, USA
Clin J Am Soc Nephrol 6:640-7. 2011..The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to identify markers of disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD)... - Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseasesVicente E Torres
Division of Nephrology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905, USA
Clin J Am Soc Nephrol 5:1312-29. 2010..If effective, lower dosages than those used to prevent rejection would minimize side effects. Combination therapy with other effective drugs could improve tolerability and results... - Treatment strategies and clinical trial design in ADPKDVicente E Torres
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Adv Chronic Kidney Dis 17:190-204. 2010..Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes... - Autosomal dominant polycystic kidney diseaseV E Torres
Division of Nephrology, Mayo Clinic, Rochester, MN, USA
Nefrologia 23:14-22. 2003 - Vasopressin in chronic kidney disease: an elephant in the room?Vicente E Torres
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Kidney Int 76:925-8. 2009.... - Autosomal dominant polycystic kidney disease: the last 3 yearsVicente E Torres
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Kidney Int 76:149-68. 2009..The purpose of this review is to update the core of knowledge in this area with recent publications that have appeared during 2006-2009... - Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney diseaseXiaofang Wang
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Nephrol Dial Transplant 24:526-34. 2009..By both mechanisms, CaR activation could lower intracellular cAMP and inhibit renal cyst growth... - Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK ratXiaofang Wang
Mayo Foundation, Rochester, Minnesota, USA
J Am Soc Nephrol 16:846-51. 2005.... - Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphateTatyana V Masyuk
Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Gastroenterology 132:1104-16. 2007.... - What the similarities of specific polycystic liver and kidney diseases can teach us about bothMarie C Hogan
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minn, USA
Nephrol News Issues 22:29-31. 2008 - Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney diseaseAngela Stroope
Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
Am J Pathol 176:1282-91. 2010..In conclusion, Pkd2ws25/- mice exhibit hepatorenal pathology resembling human autosomal dominant polycystic kidney disease and represent a useful model to study mechanisms of cystogenesis and to evaluate treatment options... - [Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotypeSertac N Kip
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Circ Res 96:873-80. 2005..This elevation can also be induced by reducing [Ca2+]i in wild-type VSMCs. The [Ca2+]i reduction and cAMP accumulation can cause an increase in both cellular proliferation and apoptosis, resembling Pkd mutant phenotype... - Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney diseaseTatyana V Masyuk
Mayo Medical School, Clinic and Foundation, 200 First St, SW, Rochester, MN 55905, USA
Am J Pathol 165:1719-30. 2004..Our results suggest that the PCK rat is a useful model for studies of biliary cystogenesis and treatment options of inherited cystic liver disease... - Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary ciliaChristopher J Ward
Division of Nephrology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Hum Mol Genet 12:2703-10. 2003..The localization of fibrocystin to cilia further strengthens that correlation and indicates that the primary defect in ARPKD may be linked to ciliary dysfunction... - The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1Denise Walker
Division of Nephrology and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
Am J Kidney Dis 41:90-4. 2003..Previously, a glutamic acid to aspartic acid polymorphism at residue 298 (E/D298) of the endothelial nitric oxide synthase (eNOS) gene ENOS was associated with disease severity in males with ADPKD... - Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK ratTatyana V Masyuk
Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Gastroenterology 125:1303-10. 2003.... - Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD)Magdalena Adeva
Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Medicine (Baltimore) 85:1-21. 2006..The current study indicates a broadened spectrum for the ARPKD phenotype and that later presenting cases with predominant liver disease should be considered part of ARPKD... - Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver diseaseMarie C Hogan
Division of Nephrology and Hypertension, Department of Biomedical STatistics and Informatics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Am Soc Nephrol 21:1052-61. 2010..In summary, octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile... - Germline PKHD1 mutations are protective against colorectal cancerChristopher J Ward
Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Hum Genet 129:345-9. 2011..0002). We also show that the carriage rate for PKHD1 mutations in the European population is higher than previous accepted at 3.2% (1:31 genomes)... - Vasopressin directly regulates cyst growth in polycystic kidney diseaseXiaofang Wang
Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Am Soc Nephrol 19:102-8. 2008..These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD... - Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney diseaseEric C Umbreit
Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
J Urol 183:183-7. 2010..We report our experience with percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney disease... - EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD ratsVicente E Torres
Division of Nephrology, Mayo Foundation, Rochester, Minnesota 55905, USA
Kidney Int 64:1573-9. 2003.... - Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney diseaseQi Qian
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Clin J Am Soc Nephrol 2:1223-7. 2007..Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary disease with prominent connective tissue manifestations. A frequent occurrence of asymptomatic pericardial effusion has been observed in patients with ADPKD... - Sirolimus reduces polycystic liver volume in ADPKD patientsQi Qian
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Am Soc Nephrol 19:631-8. 2008..In summary, treatment with sirolimus was associated with decreased polycystic liver volume, perhaps by preventing aberrant activation of mTOR in epithelial cells lining the cysts... - Analysis of the polycystins in aortic vascular smooth muscle cellsQi Qian
Division of Nephrology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Soc Nephrol 14:2280-7. 2003..These observations are consistent with an important role of the polycystins in the development, maintenance, and function of the myoelastic arterial organization and with the vascular phenotype associated with ADPKD... - Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cellsQi Qian
Department of Medicine, Division of Nephrology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Hum Mol Genet 12:1875-80. 2003.... - Polycystic kidney diseasePeter C Harris
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
Annu Rev Med 60:321-37. 2009..Rare, syndromic forms of PKD also include defects of the eye, central nervous system, digits, and/or neural tube and highlight the role of cilia and pathways such as Wnt and Hh in their pathogenesis... - Retinal arterial and venous occlusions in patients with ADPKDQi Qian
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Nephrol Dial Transplant 22:1769-71. 2007 - A complete mutation screen of the ADPKD genes by DHPLCSandro Rossetti
Division of Nephrology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Kidney Int 61:1588-99. 2002..Differentiating missense mutations and polymorphisms remains a challenge, but family-based segregation analysis is helpful... - Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapyPeter C Harris
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Curr Opin Nephrol Hypertens 15:456-63. 2006..This review explores this pathogenesis and determines the role that this knowledge is playing in the development of potential therapies... - Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney diseasePeter C Harris
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Am Soc Nephrol 17:3013-9. 2006..These insights will inform the development of targeted therapies in autosomal dominant PKD... - Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohortAndrew D Rule
Division of Nephrology, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, and University of Alabama, Birmingham, USA
J Am Soc Nephrol 17:854-62. 2006..Misclassification from changes in non-GFR factors (e.g., creatinine production, tubular secretion) conservatively biased associations with eGFR. Misclassification from method imprecision attenuated associations with creatinine clearance... - Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney diseaseMark B Consugar
Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Am J Kidney Dis 45:77-87. 2005..The common mutation, T36M, was found to have a single European origin, about 1,225 years ago. CONCLUSION: Improved haplotype analysis of ARPKD complements mutation-based diagnostics and helps trace the history of common PKHD1 mutations... - A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigreesSandro Rossetti
Division of Nephrology, Mayo Clinic, Rochester, Minnesota 55905, USA
Kidney Int 64:391-403. 2003..The ARPKD gene, PKHD1, has recently been identified. Herein we describe an effective method for PKHD1 mutation screening and the results from analysis of a novel ARPKD cohort... - Characterization of PKD protein-positive exosome-like vesiclesMarie C Hogan
Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Am Soc Nephrol 20:278-88. 2009..These data suggest that PKD proteins are shed in membrane particles in the urine, and these particles interact with primary cilia... - Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney diseaseSandro Rossetti
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Kidney Int 75:848-55. 2009..Our study indicates that the dosage of functional PKD1 protein may be critical for cyst initiation... - The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal diseaseSandro Rossetti
Division of Nephrology and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Soc Nephrol 13:1230-7. 2002..9% and 39.7%, respectively). This study has shown that the position of the PKD1 mutation is significantly associated with earlier ESRD and questions whether PKD1 mutations simply inactivate all products of the gene... - Molecular diagnostics of Meckel-Gruber syndrome highlights phenotypic differences between MKS1 and MKS3Mark B Consugar
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Hum Genet 121:591-9. 2007..This study is consistent with further genetic heterogeneity of MKS, but underlines the value of molecular diagnostics of the known genes to aid family planning decisions... - Mutations in PRKCSH cause isolated autosomal dominant polycystic liver diseaseAirong Li
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06519, USA
Am J Hum Genet 72:691-703. 2003..In light of the focal nature of liver cysts in ADPLD, the apparent loss-of-function mutations in PRKCSH, and the two-hit mechanism operational in dominant polycystic kidney disease, ADPLD may also occur by a two-hit mechanism... - Cyclic nucleotide signaling in polycystic kidney diseaseXiaofang Wang
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Kidney Int 77:129-40. 2010..This may account, in part, for increased cyclic nucleotide signaling in polycystic kidney disease and contribute substantially to disease progression... - Ciliary and centrosomal defects associated with mutation and depletion of the Meckel syndrome genes MKS1 and MKS3Rachaneekorn Tammachote
Department of Biochemistry Molecular Biology, Mayo Clinic, Rochester, MN, USA
Hum Mol Genet 18:3311-23. 2009..MKS1 and MKS3 functions are required for ciliary structure and function, including a role in regulating length and appropriate number through modulating centrosome duplication... - Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotypeSandro Rossetti
Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
Lancet 361:2196-201. 2003..Familial clustering of intracranial aneurysms suggests that genetic factors are important in the aetiology. We tested whether the germline mutation predisposes to this vascular phenotype... - The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like proteinChristopher J Ward
Division of Nephrology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
Nat Genet 30:259-69. 2002..Fibrocystin may be a receptor protein that acts in collecting-duct and biliary differentiation... - Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastographyMeng Yin
Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Magn Reson Med 58:346-53. 2007..In conclusion, MRE has the potential not only for assessing liver stiffness, but also for monitoring potential therapies for hepatic fibrosis... - Clinical profile of autosomal dominant polycystic liver diseaseQi Qian
Division of Nephrology, Mayo Clinic, Rochester, MN, USA
Hepatology 37:164-71. 2003..In conclusion, isolated ADPLD is underdiagnosed and genetically distinct from polycystic liver disease associated with ADPKD but with similar pathogenesis, manifestations, and management... - Mutations in SEC63 cause autosomal dominant polycystic liver diseaseSonia Davila
Department of Internal Medicine, Yale University School of Medicine, P O Box 208029, 333 Cedar Street, New Haven, Connecticut 06520 8029, USA
Nat Genet 36:575-7. 2004..These findings are suggestive of a role for cotranslational protein-processing pathways in maintaining epithelial luminal structure and implicate noncilial ER proteins in human polycystic disease... - Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney diseaseMaria V Irazabal
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55901, USA
Clin J Am Soc Nephrol 6:1274-85. 2011..Autosomal dominant polycystic kidney disease (ADPKD) patients have an increased risk for intracranial aneurysms (IAs). The importance of screening for unruptured IAs (UIAs) depends on their risks for growth and rupture... - PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expressionMarie C Hogan
Division of Nephrology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Hum Mol Genet 12:685-98. 2003..Low level expression was detected in many primary immune cell subtypes but up-regulated specifically in T lymphocytes, following activation signals, suggesting a role in cellular immunity... - Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantationThomas Schnelldorfer
Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Surg 250:112-8. 2009..To identify operative morbidity, mortality, and long-term outcome after operative treatment for symptomatic polycystic liver disease (PLD) and develop a treatment algorithm for patients with PLD... - Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndromeMark B Consugar
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Kidney Int 74:1468-79. 2008..Our assay improves detection levels and the reliability of molecular testing of patients with ADPKD... - Autosomal dominant polycystic kidney disease coexisting with cystic fibrosisNancy Xu
Division of Nephrology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Nephrol 19:529-34. 2006.... - Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver diseaseJayleen Grams
Department of Surgery, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
J Gastrointest Surg 11:985-90. 2007..These results suggest inferior vena cava stenting is safe and effective and should be considered as a first-line intervention in the treatment of medically intractable ascites in select patients with polycystic liver disease... - Comprehensive molecular diagnostics in autosomal dominant polycystic kidney diseaseSandro Rossetti
Division of Nephrology, Mayo Clinic, Rochester, MN 55905, USA
J Am Soc Nephrol 18:2143-60. 2007..Although nondefinite mutation data must be treated with care in the clinical setting, this study shows the potential for molecular diagnostics in ADPKD that is likely to become increasingly important as therapies become available... - Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)W CHARLES O'NEILL
Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
Am J Kidney Dis 46:1058-64. 2005..The accuracy and precision of ultrasonography (US) in assessing the severity of autosomal dominant polycystic kidney disease (ADPKD) is unknown... - The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk ratUrsula M Smith
Section of Medical and Molecular Genetics, Division of Reproductive and Child Health, University of Birmingham Medical School, Birmingham B15 2TT, UK
Nat Genet 38:191-6. 2006..It encodes a 995-amino acid seven-transmembrane receptor protein of unknown function that we have called meckelin... - Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conferenceMeral Gunay-Aygun
National Human Genome Research Institute, the Molecular Imaging Program, National Cancer Institute, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1851, USA
J Pediatr 149:159-64. 2006 - Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohortArlene B Chapman
Department of Medicine Renal Division, University of Alabama at Birmingham, Birmingham, Alabama, USA
Kidney Int 64:1035-45. 2003.... - Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney diseaseBernard F King
Department of Medicine (Renal Division, University of Alabama, Birmingham, Alabama, USA
Kidney Int 64:2214-21. 2003.... - Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomesJared J Grantham
Kansas University Medical Center, Kansas City, Kansas, USA
Clin J Am Soc Nephrol 1:148-57. 2006.... - Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonistVincent H Gattone
Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, Indiana 46202, USA
Nat Med 9:1323-6. 2003..These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered... - Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney diseaseGordon F Gibbs
Department of Diagnostic Radiology, Mayo Foundation, Rochester, Minnesota 55905, USA
Kidney Int 65:1621-7. 2004..These data do not support widespread screening for intracranial aneurysms in the ADPKD population... - Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohortKyongtae T Bae
Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
Clin J Am Soc Nephrol 1:64-9. 2006..Hepatic cysts are more prevalent and larger in total cyst volume in women than in men. Hepatic cyst prevalence and aggregate total hepatic cyst volume increased with age... - Duodenal diverticulosis in autosomal dominant polycystic kidney diseaseSumedha Kumar
Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Nephrol Dial Transplant 21:3576-8. 2006 - Cerebral aneurysmsVicente E Torres
N Engl J Med 355:2703-4; author reply 2705. 2006 - Water for ADPKD? Probably, yesVicente E Torres
J Am Soc Nephrol 17:2089-91. 2006 - Treatment of polycystic liver disease: one size does not fit allVicente E Torres
Am J Kidney Dis 49:725-8. 2007
Research Grants
- KIDNEY DISEASE RESEARCH TRAINING PROGRAMVicente Torres; Fiscal Year: 2007..abstract_text> ..
- Novel treatments for polycystic kidney diseaseVicente Torres; Fiscal Year: 2007....
- Controlled Trial of Renin Angiotensin Blockade in ADPKDVicente Torres; Fiscal Year: 2007..Approximately one-half of these patients will have normal or near-normal renal function and one-half have mild to moderate renal insufficiency. The protocols for the Pilot Study will be conducted only at the Mayo Clinic. ..
- Polycystic Kidney Disease: Innovative Imaging to Assess Progression (PCC)Vicente Torres; Fiscal Year: 2007....
- Novel treatments for polycystic kidney diseaseVicente Torres; Fiscal Year: 2009..abstract_text> ..
- REDOX, ACID/BASE, AND PATHOGENESIS OF ADPKDVicente Torres; Fiscal Year: 2002..The main thrust of the proposed studies is directed towards the identification of pathogenetic mechanisms than can be subject to preventive and therapeutic interventions. ..
- RENIN ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF ADPKDVicente Torres; Fiscal Year: 1993..The results of these studies will augment the understanding of the pathogenesis of cyst formation and hypertension in ADPKD and are likely to have a significant impact on the treatment of this disease...
- Novel treatment for polycystic kidney diseaseVicente E Torres; Fiscal Year: 2010....